{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:14:29Z","timestamp":1759335269235},"reference-count":20,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0534-z","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T11:24:06Z","timestamp":1551266646000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report"],"prefix":"10.1136","volume":"7","author":[{"given":"Teppei","family":"Sugano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Funasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuka","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rintaro","family":"Noro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Gemma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"issue":"10027","key":"534_CR1","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.","journal-title":"Lancet."},{"issue":"19","key":"534_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"key":"534_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"issue":"11","key":"534_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206\u201312.","journal-title":"JAMA Dermatol"},{"key":"534_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.lungcan.2017.04.019","volume":"109","author":"T Uenami","year":"2017","unstructured":"Uenami T, Hosono Y, Ishijima M, Kanazu M, Akazawa Y, Yano Y, et al. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report. Lung Cancer. 2017;109:42\u20134.","journal-title":"Lung Cancer"},{"issue":"3","key":"534_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","volume":"74","author":"SJ Hwang","year":"2016","unstructured":"Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455\u201361 e1.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"534_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cup.12858","volume":"44","author":"JL Curry","year":"2017","unstructured":"Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158\u201376.","journal-title":"J Cutan Pathol"},{"issue":"3","key":"534_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2559.1994.tb00519.x","volume":"24","author":"JT O'Grady","year":"1994","unstructured":"O'Grady JT, Shahidullah H, Doherty VR, al-Nafussi A. Intravascular histiocytosis. Histopathology. 1994;24(3):265\u20138.","journal-title":"Histopathology"},{"issue":"3","key":"534_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1046\/j.1365-2133.1999.02717.x","volume":"140","author":"E Rieger","year":"1999","unstructured":"Rieger E, Soyer HP, Leboit PE, Metze D, Slovak R, Kerl H. Reactive angioendotheliomatosis or intravascular histiocytosis? An immunohistochemical and ultrastructural study in two cases of intravascular histiocytic cell proliferation. Br J Dermatol. 1999;140(3):497\u2013504.","journal-title":"Br J Dermatol"},{"issue":"6","key":"534_CR10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/j.1365-2133.2005.06618.x","volume":"152","author":"A Okazaki","year":"2005","unstructured":"Okazaki A, Asada H, Niizeki H, Nonomura A, Miyagawa S. Intravascular histiocytosis associated with rheumatoid arthritis: report of a case with lymphatic endothelial proliferation. Br J Dermatol. 2005;152(6):1385\u20137.","journal-title":"Br J Dermatol"},{"issue":"9","key":"534_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/cup.12613","volume":"42","author":"E Barba","year":"2015","unstructured":"Barba E, Colato C, Girolomoni G. Intralymphatic Histiocytosis: a case report and review of literature. J Cutan Pathol. 2015;42(9):593\u20139.","journal-title":"J Cutan Pathol"},{"issue":"2","key":"534_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/DAD.0b013e3181986cc2","volume":"31","author":"L Requena","year":"2009","unstructured":"Requena L, El-Shabrawi-Caelen L, Walsh SN, Segura S, Ziemer M, Hurt MA, et al. Intralymphatic histiocytosis. A clinicopathologic study of 16 cases. Am J Dermatopathol. 2009;31(2):140\u201351.","journal-title":"Am J Dermatopathol"},{"key":"534_CR13","first-page":"183","volume":"3","author":"A Perdriger","year":"2009","unstructured":"Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics. 2009;3:183\u201391.","journal-title":"Biologics"},{"issue":"1","key":"534_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/archdermatol.2010.407","volume":"147","author":"M Sakaguchi","year":"2011","unstructured":"Sakaguchi M, Nagai H, Tsuji G, Morinobu A, Kumagai S, Nishigori C. Effectiveness of infliximab for intralymphatic histiocytosis with rheumatoid arthritis. Arch Dermatol. 2011;147(1):131\u20133.","journal-title":"Arch Dermatol"},{"issue":"5","key":"534_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaad.2013.11.024","volume":"70","author":"F Bakr","year":"2014","unstructured":"Bakr F, Webber N, Fassihi H, Swale V, Lewis F, Rytina E, et al. Primary and secondary intralymphatic histiocytosis. J Am Acad Dermatol. 2014;70(5):927\u201333.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"534_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","volume":"14","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Thompson JA. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract. 2018;14(4):247\u20139.","journal-title":"J Oncol Pract"},{"issue":"4","key":"534_CR17","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/j.cgh.2016.09.017","volume":"15","author":"S Yanai","year":"2017","unstructured":"Yanai S, Nakamura S, Matsumoto T. Nivolumab-induced colitis treated by infliximab. Clin Gastroenterol Hepatol. 2017;15(4):e80\u2013e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"305","key":"534_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","volume":"26","author":"RH Mole","year":"1953","unstructured":"Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234\u201341.","journal-title":"Br J Radiol"},{"key":"534_CR19","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28780","volume":"3","author":"AM Grimaldi","year":"2014","unstructured":"Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3:e28780.","journal-title":"Oncoimmunology."},{"issue":"20","key":"534_CR20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in stage III non-small-cell lung Cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0534-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:46:59Z","timestamp":1601056019000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0534-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0534-z","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]},"assertion":[{"value":"11 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the patient for the analysis of the samples and the tissues.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the patient. A copy of the written consent is available for review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Masahiro Seike, Kaoru Kubota, and Akihiko Gemma have received honorarium from Merck Sharp & Dohme. The authors report no other conflicts of interest in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"59"}}